News
CDXC
3.690
+0.55%
0.020
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
ChromaDex Corp. Announces its flagship Tru Niagen product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program. AlkeMist Labs is a leading testing laboratory known for its rigorous herbal and dietary supplement analysis. The company is the number one healthy-aging NAD+ supplement company in the United States. TruNiagen features the most efficient, patented, superior quality NAD+ precursor on the market.
Barchart · 2d ago
Weekly Report: what happened at CDXC last week (0318-0322)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Fresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. Akso Health Group stock moved upwards by 29.0%. ChromaDex stock rose upwards by 27.91%. Trxade Health shares declined by 33.0% during the session.
Benzinga · 03/18 17:31
Weekly Report: what happened at CDXC last week (0311-0315)?
Weekly Report · 03/18 12:04
Weekly Report: what happened at CDXC last week (0304-0308)?
Weekly Report · 03/11 11:59
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/11 11:33
ChromaDex Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/11 11:33
HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6
Benzinga · 03/11 11:23
CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
ChromaDex just reported results for the fourth quarter of 2023. The company did not report any EPS for the quarter. ChromaDex reported revenue of $21.20 million. This was 1.03% better than the analyst estimate of $20.98 million.
Investorplace · 03/07 02:53
Chromadex Releases Insightful Corporate Presentation Online
TipRanks · 03/06 21:13
Press Release: ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results. Fourth quarter net sales of $21.2 million, gross margin of 61.0%, and net income of $0.1 million. Full year net sales of $83.6 million, up 16% from the prior year.
Dow Jones · 03/06 21:04
Press Release: ChromaDex Corporation Reports -3-
The company expects to report a net loss of $1.9 million for the first quarter of 2022. The Company expects to earn $1,000 million in the second quarter. The company has a target for Adjusted EBITDA of $2.5 million. The Company has a long-term target of $10 million. The stock price of the company is expected to rise to $20.
Dow Jones · 03/06 21:04
*ChromaDex 4Q Loss/Shr 2c >CDXC
Dow Jones · 03/06 21:04
Earnings Scheduled For March 6, 2024
Foot Locker is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion. JD.com is expected to report earnings for its fourth quarter. CTS is estimated to report its quarterly earnings before the bell. Other companies reporting before the Bell include Campbell Soup, Super Group and Abercrombie & Fitch.
Benzinga · 03/06 10:00
Notable earnings after Wednesday's close
Seeking Alpha · 03/05 22:35
ChromaDex Q4 2023 Earnings Preview
ChromaDex Corporation (CDXC) is scheduled to announce Q4 earnings results on March 6th. The consensus EPS Estimate is -$0.02 and the consensus revenue estimate is $20.74M. Over the last 1 year, CDXC has beaten EPS estimates 75% of the time.
Seeking Alpha · 03/05 22:35
Weekly Report: what happened at CDXC last week (0226-0301)?
Weekly Report · 03/04 12:02
Weekly Report: what happened at CDXC last week (0219-0223)?
Weekly Report · 02/26 12:21
Press Release: ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024. The Company will hold a conference call to discuss its financial results for the fourth quarter, which ended December 31, 2023. ChromaDex is a global bioscience company dedicated to healthy aging.
Dow Jones · 02/21 13:33
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
ChromaDex Corp. Will hold a conference call on March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The company is a global bioscience company dedicated to healthy aging. The conference call will be broadcast live and available for replay.
Barchart · 02/21 07:32
More
Webull provides a variety of real-time CDXC stock news. You can receive the latest news about Chromadex Corp through multiple platforms. This information may help you make smarter investment decisions.
About CDXC
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.